论文信息 - Neratinib after trastuzumab in patients with HER2-positive breast cancer - Author's reply. - 字舞流文

Neratinib after trastuzumab in patients with HER2-positive breast cancer - Author's reply.

M. Buyse | A. Chan | B. Yao

[1] M. Buyse,et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. , 2016, The Lancet. Oncology.